All News
Systemic Steroids Seldom Flare Psoriasis
A tenet of drug management suggests that steroid use in psoriasis may be associated with rebound flares; well this has been challenged by a new observational trial showing that the risk of flares (and severe flares) of psoriasis flares were seldom triggered by systemic steroids - certainly much l
Read Article
Upadacitinib Effective in Biologic Refractory Psoriatic Arthritis
The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.
Read Article
Dr. Connie Hsia from #UTSW shows that the frequency of #Sarcoidosis is increasing; there is familial clustering, higher risk in firefighters, WTC, insecticides, construction, organic dust, fumes, smokers https://t.co/hDQV4MmZNt
Dr. John Cush RheumNow ( View Tweet)
Medicare Physician Fee Schedule Final Rule Released
https://t.co/UvGQ5PIQEk https://t.co/ZuivQr5jKO
Links:
Dr. John Cush RheumNow ( View Tweet)
Read our article, Mortality in Low Dose Prednisone by Dr. Eric Dein ( @ejdein1) , covering #ACR20 abstracts.
https://t.co/y6dL9V6iDC https://t.co/c39ovUJAPz
Links:
Dr. John Cush RheumNow ( View Tweet)
Pregnancy and ILD: Dr. David Liew ( @drdavidliew) reviews abstract #1446 presented at #ACR20.
https://t.co/1g5KUdG6XW
Links:
Dr. John Cush RheumNow ( View Tweet)
Hepatitis B, RA and Drug Risk with Drs. Stanley Cohen and Jack Cush #ACR20
https://t.co/jOzAkLzNEc https://t.co/A377Ti9zvX
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD :Largest to date cohort study of pregnancies in women w/ ILD showed no mat. deaths suggesting that women w/ ILD may not need to avoid conception or terminate pregnancies, but pts w/ severe ILD were at higher risk for poor pregnancy outcomes.
Dr. John Cush RheumNow ( View Tweet)
GCA Treatment Data: Dr. David Liew ( @drdavidliew) reviews abstracts #0516 and #0513 presented at the #ACR20.
https://t.co/Czi0jiHa00 https://t.co/uGEaFWGpIC
Links:
Dr. John Cush RheumNow ( View Tweet)
A look back on Day 5 of #ACR20. Listen to more recaps at the RheumNow podcast found on Apple and Android devices.
https://t.co/sd0J9ZnRpK
Links:
Dr. John Cush RheumNow ( View Tweet)
Delays in Diagnosis - Axial Spondyloarthritis: Dr Antoni Chan ( @synovialjoints) reviews abstracts #1303 and #1306 presented at the #ACR20.
https://t.co/k7L2ebXcGb https://t.co/6oQ8fWpVCQ
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrMiniDey : Plenty of great telemed posters in ""Measures; Measurement of Healthcare Quality"" session! Abs#1584 reports telemedicine improves access to #rheum clinics; adherence, eg in those prev without adequate transport provision.
https://t.co/BbTnprwbat https://t.co/d8lbs2b8Ca
Links:
Dr. John Cush RheumNow ( View Tweet)
Read our latest titled: "ACIP Recommendations for Pfizer Vaccine Candidate" by Dr. Rachel Tate ( @uptoTate )
https://t.co/aTUoGTFrbh https://t.co/NpwrGTc0ZU
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @doctorRBC : Deucravacitinib TYK2i for PsA
Phase2b 16wk, Double-blind, Placebo, RCT
⬆️ACR20/50/70 response vs. PBO
⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO
*⃣No serious AE
@RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/LeMBj3XQo4" https://t.co/U9fB5hgcJY
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : Big wins for #pedirheum!
#FDA had approved for JIA;2 y.o:
9/29 golimumab iV for JIA/PsA
9/25 tofacitinib (weight based dosing) for polyarticular JIA (tofacitinib dosing for JIA: 10 kg-20kg: 3.2 mg bid, for 20-40 kg 4 mg bid, for 40 kg 5 mg bid)
Dr. John Cush RheumNow ( View Tweet)
ABCs of RA: Panel Discussion with Dr. Jonathan Kay #acr20
https://t.co/9HTTyPjCBV https://t.co/uDtS2EsMng
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Abst#1993 main finding: no difference in primary outcome in Medicare study of MTX vs HCQ MACE events. Secondary analys: greater stroke risk, lower MI and hospitalized HF in MTX pts but hard to know what is causal in large database study. https://t.co/h9wAKkSlVa
Dr. John Cush RheumNow ( View Tweet)
Phase II/III, double-blind, RCT shown fasinumab (nerve growth factor inhibitor) at higher doses (9mg q4 or q8wks), but not lower doses, improved chronic low back pain w/ best responses at wk 16.. Rapid OA progression seen more w/ FAS (3.8%) vs PBO (0.7%) https://t.co/OfdEsAZuDe
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : ⬆️General provider awareness of IgG4-RD reflected in ⬆️IgG subclass testing but number of IgG4-RD dx did not change.
⬆️testing for hepatobiliary and orbital dz
⬇️testing retroperitoneal fibrosis
#ACR20 Abs#1619 https://t.co/IkzrLfeJ7d https://t.co/gShfJaxwNA
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @uptoTate : March 2020 telemed implementation in WI; CA, no-show rates decreased; total visit volume remained ^. Partic. true for rural offices, while urban ctr didn't see red. no-show rates. ? healthcare delivery disparities #ABS0603 https://t.co/WJcUT14KBc https://t.co/GSNqXoGzl6
Links:
Dr. John Cush RheumNow ( View Tweet)